All News

Article

Practical use of JAK inhibitors in select groups in Axial SpA

Antoni Chan, MD, PhD Nov 12, 2022

A new treatment for AxSpA that has come on the scene are JAK inhibitors. In clinic, considerations for JAKi use are body mass index, smoking status, prior use of biologics and patients with high inflammatory states such as high CRP and inflammatory change on MRI scan of the spine and sacroiliac joints. There are further studies at #ACR22 which help answer these questions.

Article

Do biologics help taper steroids in Adult Still’s Disease?

Bella Mehta, MBBS, MS Nov 12, 2022

A Japanese large scale claims data study was able to collect 5-year data to study the treatment patterns in Still’s. In May 2019, intravenous tocilizumab was approved in Japan for Still’s disease. The study was designed to see patterns of steroid exposure before and after the approval of this therapy.

@KenSaag, ACR president describes the challenges to rheumatologists including physician shortages and need for more diversity at #ACR22 opening session. "You cannot be what you cannot see" Room 108 at NOON - find out what @ACRheum and @ACRheumDC will do. @RheumNow @CreakyJoints https://t.co/8KV6vDalNu

https://twitter.com/ericdeinmd/status/1590108687804370945

#ACR22 Opening Plenary. Dr Saag championed the importance of funding and support to early career researchers, team science, translational science and public health @RheumNow https://t.co/pgSZ1twgG3

Kicking things off with South Philly Barbacoa! #ACR22 #ACRTacoFest #ACRTacoTrot #RheumPix @AliDuarteMD @rheumecraig @BharatKumarMD @maio_danila @SattuiSEMD @RheumNow https://t.co/cxoCuYesDZ

Look at these graphs and try and tell me that sex and gender doesn't matter in RA. We have seen in study after study after study - sex and gender matters. ABST0241 @erasmusmcintl #ACR22 @RheumNow https://t.co/GQnKrAp0eB https://t.co/MxHRy2kwDN

https://twitter.com/TheLancetRheum/status/1572873396123504641

What's the difference between RA and PsA on hand MRI? Removing our cognitive biases, here's what a neural network has to say (not hard to see the power of this work) ABST0242 @LkasDer @maier_ak #ACR22 @DrCMcMaster @RheumNow https://t.co/TqS6xUZNtl

Abst0327 #ACR22 SMART-SLE Monitoring Some SLE patients with +dsDNA have persistent positivity, others have fluctuations Anti-dsDNA in persistently positive HR 1.56 for flare risk Change (up or down!) in dsDNA more than 2x prior visit for fluctuating patients: HR 1.43 @RheumNow https://t.co/YwDPTYWPLu

It's always amazed me adalimumab & abatacept, have very different MOA but similar efficacy in RA - on a population level. Not for individuals, though. Surely we can pick the winners better? Lovely biomarker work from a H2H RCT ABST0244 #ACR22 @RheumNow https://t.co/qVttIZSQtc

Abst0324 #ACR22 How close are we to measuring Interferon Signature in clinical practice? NCounter and BioFire assays studied - correlated well we each other Genes: IFI27, IFI44L, IFIT1, RSAD2 SLE higher than RA or FMS, but does not correlate with SLE activity @RheumNow https://t.co/izpFtj9Pcd

Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SLE compared to controls AwMA predictive of death, AmtDNA and AmtRNA predictive of nephritis @Rheumnow https://t.co/d98HSHnJVE

What if my patient with RA or PsA gets pregnant? @RheumNow #ACR22 Abstract #1786; 34 women 👶 Disease scores improved during #pregnancy and increased #postpartum 👶20-27% of women required a cesarean delivery 👶mean delivery 39-40 weeks gestation 👶 1 NICU admission https://t.co/qYPaB6TcDJ

JAK inhibitors in RA: does their performance vary in the real world? @opal_ltd 🇦🇺: n= 5900 JAKi-treated RA pts, 2015-2021 upa is relatively new in Australia, but amazing how bari and tofa are so similar (same with the data on switching reason too) ABST0274 #ACR22 @RheumNow https://t.co/63PrRVAzk5

Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis Factors for SLE transition: younger age, serositis, dsDNA SSc transition: puffy finger, NFC, or SSc antibodies No studies wo moderate or high risk of bias Limited studies on biomarkers for SLE, need more studies @Rheumnow https://t.co/GofGF8TkCx

Time check!⌚🦉 This roaming clockface helps me navigate through time zones while attending #ACR22 ✈️virtually jetlagged but having fun!🤓 @RheumNow @rheumarhyme @doktora_ging #RheumPix https://t.co/HgTcIyw7ej

Infections in JAKi v TNFi in RA We've seen ORAL Surveillance data What about East Asian pts, with enriched zoster risk? National KOR🇰🇷 insurance data: Bacterial: equal Opportunistic: TNFi worse Zoster: JAKi worse serious zoster a lot more common here! ABST0302 #ACR22 @RheumNow https://t.co/lxsbY1Nf9N

“Conflict, crisis and resolution make a story. A good story has drama where there is desire with danger.” @cuttingforstone author, Dr. Verghese noted the COVID19 #pandemic has all of these elements. It is a good story, but we don’t know the resolution. @Rheumnow #ACR22 https://t.co/Tomev2SYcT

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.

Let’s do this #ACR22 ⁦@RheumNow⁩ #rheumpix https://t.co/zTx4TynK44

AS, Lupus and Subclinical RA: What I'm looking forward to at #ACR22 There are three areas that always draw my attention each conference and this time is no different... https://t.co/1h7NRgcqCm https://t.co/9P1UwrmjxW

https://bit.ly/3UuvLRN

Topics

All News

Practical use of JAK inhibitors in select groups in Axial SpA

Do biologics help taper steroids in Adult Still’s Disease?

Do you get our email newsletter?